相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma
Alina Naveed et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2021)
Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases
Yoshitsugu Aoki et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
Comprehensive in vivo secondary structure of the SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms
Nicholas C. Huston et al.
MOLECULAR CELL (2021)
FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES
Ewen Callaway
NATURE (2021)
New variant of SARS-CoV-2 in UK causes surge of COVID-19
Tony Kirby
LANCET RESPIRATORY MEDICINE (2021)
In vivo structural characterization of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs
Lei Sun et al.
CELL (2021)
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
Alona Kuzmina et al.
CELL HOST & MICROBE (2021)
Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome
Valeria Lulla et al.
JOURNAL OF VIROLOGY (2021)
Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
Nicholas G. Davies et al.
NATURE (2021)
Antisense technology: an overview and prospectus
Stanley T. Crooke et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Efficient Inhibition of SARS-CoV-2 Using Chimeric Antisense Oligonucleotides through RNase L Activation**
Xiaoxuan Su et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
Tsuyoshi Yamamoto et al.
PHARMACEUTICS (2021)
Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
Hao Cui et al.
ACS OMEGA (2021)
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
Pavel Drevinek et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma
Elisa Taiana et al.
LEUKEMIA (2020)
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou et al.
NATURE (2020)
First Case of 2019 Novel Coronavirus in the United States
Michelle L. Holshue et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2020)
Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles
Parikshit Moitra et al.
ACS NANO (2020)
The Architecture of SARS-CoV-2 Transcriptome
Dongwan Kim et al.
CELL (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-a, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2020)
Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs
Sayeed Ur Rehman et al.
CLINICAL SCIENCE (2020)
Targeting Ephrin Receptor Tyrosine Kinase A2 with a Selective Aptamer for Glioblastoma Stem Cells
Alessandra Affinito et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look
Ramya Rangan et al.
RNA (2020)
STUDY DESIGN AND RATIONALE OF HELIOS-B: A PHASE 3 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF VUTRISIRAN IN PATIENTS WITH ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
Rebecca Shilling et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
The powerful world of antisense oligonucleotides: From bench to bedside
Anais M. Quemener et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Bette Korber et al.
CELL (2020)
Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection
Christoph B. Messner et al.
CELL SYSTEMS (2020)
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
Young Hun Chung et al.
ACS NANO (2020)
Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides
Mehran Nikan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Emerging viral mutants in Australia suggest RNA recombination event in the SARS-CoV-2 genome
Ting-Yu Yeh et al.
MEDICAL JOURNAL OF AUSTRALIA (2020)
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Alexandre J. Debacker et al.
MOLECULAR THERAPY (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements
Ilaria Manfredonia et al.
NUCLEIC ACIDS RESEARCH (2020)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides
Yanfeng Wang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2019)
Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p. Phe508del cystic fibrosis
Wouter Beumer et al.
PLOS ONE (2019)
Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease
Marine Imbert et al.
NUCLEIC ACID THERAPEUTICS (2019)
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
Maria K. Tsoumpra et al.
EBIOMEDICINE (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer
Silvia Nuzzo et al.
CANCERS (2019)
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Isabelle Sermet-Gaudelus et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc et al.
NATURE NANOTECHNOLOGY (2019)
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery
Silvia Catuogno et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Locked nucleic acid: modality, diversity, and drug discovery
Peter H. Hagedorn et al.
DRUG DISCOVERY TODAY (2018)
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity
Nicola Amodio et al.
LEUKEMIA (2018)
Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer
Vikash Reebye et al.
ONCOGENE (2018)
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
Alison M. Blain et al.
PLOS ONE (2018)
Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver
Colton M. Miller et al.
NUCLEIC ACID THERAPEUTICS (2018)
Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo
Hassan Javanbakht et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Antibody-Antisense Oligonucleotide Conjugate Downregulates a Key Gene in Glioblastoma Stem Cells
Amy E. Arnold et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1
Jessica Chery et al.
NUCLEIC ACID THERAPEUTICS (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
Graham McClorey et al.
BIOMEDICINES (2018)
Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations
Lulu Huang et al.
GENOME BIOLOGY (2018)
Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice
Jeff R. Crosby et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Xue-Hai Liang et al.
MOLECULAR THERAPY (2017)
Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer
Jon Voutila et al.
MOLECULAR THERAPY (2017)
FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein et al.
MOLECULAR THERAPY (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
Naoki Iwamoto et al.
NATURE BIOTECHNOLOGY (2017)
A non-coding function of TYRP1 mRNA promotes melanoma growth
David Gilot et al.
NATURE CELL BIOLOGY (2017)
Porphyria
D. Montgomery Bissell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
Michael Tanowitz et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense Oligonucleotides Targeting Raf-1 Block Japanese Encephalitis Virus In Vitro and In Vivo
Li Zhang et al.
NUCLEIC ACID THERAPEUTICS (2017)
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Molecular Mechanisms of Antisense Oligonucleotides
Stanley T. Crooke
NUCLEIC ACID THERAPEUTICS (2017)
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Yuanyu Huang
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chiranjib Chakraborty et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
Sebastien A. Burel et al.
NUCLEIC ACIDS RESEARCH (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
A microRNA switch regulates the rise in hypothalamic GnRH production before puberty
Andrea Messina et al.
NATURE NEUROSCIENCE (2016)
Antisense Oligonucleotides Targeting Influenza A Segment 8 Genomic RNA Inhibit Viral Replication
Elzbieta Lenartowicz et al.
NUCLEIC ACID THERAPEUTICS (2016)
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Aurelie Goyenvalle et al.
NATURE MEDICINE (2015)
In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122
Soren Ottosen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Linyan Meng et al.
NATURE (2015)
Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
Robert A. Fey et al.
INHALATION TOXICOLOGY (2014)
Antisense therapy for hepatitis C virus infection
Ype P. de Jong et al.
JOURNAL OF HEPATOLOGY (2014)
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
Amanda J. Ward et al.
NUCLEIC ACIDS RESEARCH (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent
Lykke Pedersen et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2014)
Mipomersen Sodium: First Global Approval
Philip Hair et al.
DRUGS (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Thurman M. Wheeler et al.
NATURE (2012)
Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections
Patrick L. Iversen et al.
VIRUSES-BASEL (2012)
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
Corinne Betts et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Silencing of microRNA families by seed-targeting tiny LNAs
Susanna Obad et al.
NATURE GENETICS (2011)
Huntington's Disease
Steven Finkbeiner
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers
Natee Jearawiriyapaisarn et al.
CARDIOVASCULAR RESEARCH (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
Ellen Marie Straarup et al.
NUCLEIC ACIDS RESEARCH (2010)
No-go decay: a quality control mechanism for RNA in translation
Yuriko Harigaya et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2010)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
A Amantana et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers
BW Neuman et al.
JOURNAL OF VIROLOGY (2005)
TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA
XC Bo et al.
BIOINFORMATICS (2005)
Secondary structure prediction of interacting RNA molecules
M Andronescu et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Sfold web server for statistical folding and rational design of nucleic acids
Y Ding et al.
NUCLEIC ACIDS RESEARCH (2004)
Thermodynamic criteria for high hit rate antisense oligonucleotide design
OV Matveeva et al.
NUCLEIC ACIDS RESEARCH (2003)
Mfold web server for nucleic acid folding and hybridization prediction
M Zuker
NUCLEIC ACIDS RESEARCH (2003)
Fomivirsen - Clinical pharmacology and potential drug interactions
RS Geary et al.
CLINICAL PHARMACOKINETICS (2002)
The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase
M Koziolkiewicz et al.
BLOOD (2001)
Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond
Y Ding et al.
NUCLEIC ACIDS RESEARCH (2001)
Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
M Faria et al.
NATURE BIOTECHNOLOGY (2001)
Developing aptamers into therapeutics
RR White et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity
OV Matveeva et al.
NUCLEIC ACIDS RESEARCH (2000)
Effects of RNA secondary structure on cellular antisense activity
TA Vickers et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
